Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...
The deficiencies noted in the CRL were not related to efficacy or safety data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Abeona Therapeutics regarding the ...
Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients with DEB experience ocular complications. A single patient showed complete ...
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its ...
Treatment with pz-cel resulted in statistically significant and clinically meaningful improvements in wound healing and pain reduction. The Food and Drug Administration (FDA) has accepted for Priority ...
PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization ...
Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional VYJUVEK was approved by the FDA in the ...
Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results